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Costello syndrome (CS) patients suffer from a very high 10% incidence of embryonal 
rhabdomyosarcoma (ERMS). As tools to discover targeted therapeutic leads, we used 
a CS patient-derived ERMS cell line (CS242 ERMS) harboring a homozygous p.G12A 
mutation in HRAS, and a control cell line derived from the same patient comprising 
non-malignant CS242 fibroblasts with a heterozygous p.G12A HRAS mutation. A library 
of 2,000 compounds with known pharmacological activities was screened for their effect 
on CS242 ERMS cell viability. Follow-up testing in a panel of cell lines revealed that 
various compounds originally developed for other indications were remarkably selective; 
notably, the phosphodiesterase (PDE) inhibitor zardaverine was at least 1,000-fold more 
potent in CS242 ERMS than in the patient-matched non-malignant CS242 fibroblasts, 
other ERMS, or normal fibroblasts. Chronic treatment with zardaverine led to the emer-
gence of resistant cells, consistent with CS242 ERMS comprising a mixed population of 
cells. Many PDE inhibitors in addition to zardaverine were tested on CS242 ERMS, but 
almost all had no effect. Interestingly, zardaverine and analogs showed a similar cyto-
toxicity profile in CS242 ERMS and cervical carcinoma-derived HeLa cells, suggesting a 
mechanism of action common to both cell types that does not require the presence of an 
HRAS mutation (HeLa contains wild type HRAS). Two recent studies presented possible 
mechanistic explanations for the cytotoxicity of zardaverine in HeLa cells. One revealed 
that zardaverine inhibited a HeLa cell-based screen measuring glucocorticoid receptor 
(GR) activation; however, using engineered HeLa cells, we ruled out a specific effect 
of zardaverine on signaling through the GR. The second attributed zardaverine toxicity 
in HeLa cells to promotion of the interaction of phosphodiesterase 3A and the growth 
regulatory protein Schlafen 12. We speculate that this work may provide a possible 
mechanism for zardaverine action in CS242 ERMS, although we have not yet tested this 
hypothesis. In conclusion, we have identified zardaverine as a potent cytotoxic agent in 
a CS-derived ERMS cell line and in HeLa. Although we have ruled out some possibilities, 
the mechanism of action of zardaverine in CS242 ERMS remains to be determined.
Keywords: sarcoma, costello syndrome, high-throughput screening, phosphodiesterase, inhibitor, cytotoxicity, 
cell viability
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inTrODUcTiOn
Embryonal rhabdomyosarcoma (ERMS) is the most common 
pediatric soft tissue sarcoma, and its incidence is significantly 
increased in children with Costello syndrome (CS), a rare genetic 
disorder resulting from heterozygous germline mutations in the 
proto-oncogene HRAS located on 11p15.5 (1–5). ERMS associ-
ated with either p.G12S, p.G12C, or p.G12A mutations occurs 
with a very high lifetime incidence of 10% (6, 7). In the vast 
majority of CS-derived ERMS cases, patients carry a paternally 
inherited HRAS mutation and tumors display paternal uniparen-
tal disomy with loss of the maternally inherited chromosome 11 
(8). The incomplete success to date of treating CS-derived ERMS 
patients highlights a need for better therapeutic options; out of 13 
patients who received treatment, 3 died due to tumor progression 
or relapse (8).
Nemours has established a CS registry and tissue repository 
unparalleled in scope, allowing us to establish a CS patient-
derived ERMS cell line harboring a homozygous p.G12A muta-
tion in HRAS (CS242 ERMS), as well as a control cell line from the 
same patient comprising non-malignant CS242 fibroblasts with a 
heterozygous p.G12A mutation. Using these cell lines, we endeav-
ored to discover compounds selectively toxic to ERMS harboring 
a homozygous HRAS mutation. Such compounds could lead to 
chemical probes to further understanding of the biological basis 
of malignancy in CS patients, and ultimately to therapeutic leads. 
We chose to screen using a phenotypic assay of cell viability rather 
than an assay explicitly targeted to HRAS signaling to provide 
insights into disease biology and therapeutic opportunities by 
uncovering active compounds with unanticipated molecular 
target(s) and mechanism of action.
We screened a library of FDA-approved drugs and other 
compounds that have undergone clinical testing to determine if 
any of these compounds could be “repurposed” to block ERMS 
harboring mutant HRAS. These compounds generally have good 
physicochemical properties, and many have been shown to 
modulate specific molecular targets, providing the basis for testable 
mechanism of action hypotheses. Zardaverine, previously devel-
oped as a phosphodiesterase (PDE) inhibitor (9, 10), displayed 
cell killing in CS-derived ERMS harboring homozygous mutant 
HRAS. Strikingly, zardaverine had no effect on the growth of any 
other cell lines tested with the exception of HeLa. Here, we describe 
characterization of the activity and selectivity of this compound, 
and initial studies to provide clues as to mechanism of action.
MaTerials anD MeThODs
Materials
Expression Vectors and Transfection Reagents
GL4.36[luc2P/MMTV/Hygro], pGL4.54[luc2/TK], and 
pNL1.1.TK[Nluc/TK] were from Promega (Madison, WI, USA). 
Lipofectamine 3000 was from Life Technologies (Grand Island, 
NY, USA).
Cell Culture and Assay Development Supplies
Dulbecco’s modified Eagle’s medium (DMEM), phenol red-
free DMEM, Roswell Park Memorial Institute (RPMI) 1640, 
phosphate-buffered saline (PBS) without calcium and magnesium, 
0.25% trypsin in Hanks’ balanced salt solution without calcium 
and magnesium, and heat inactivated fetal bovine serum (FBS) 
were from Corning (Corning, NY, USA). Charcoal-stripped FBS 
was from Gemini Bio-Products (West Sacramento, CA, USA). 
McCoy’s 5A medium modified was from American Type Culture 
Collection (ATCC, Manassas, VA, USA). l-Glutamine (200 mM) 
and l-glutamine (200  mM)/penicillin (10,000  U)/streptomycin 
(10,000 μg) mixtures were from Life Technologies (Grand Island, 
NY, USA). Dimethyl sulfoxide (DMSO; Hybri-Max™, sterile 
filtered, BioReagent, suitable for hybridoma, ≥99.7% pure) was 
from Sigma-Aldrich (St. Louis, MO, USA). Sterile conical tubes, 
CoolCell cryogenic vial freezing containers, tissue culture (TC)-
treated T-flasks, dishes, and 6-well plates, were from Corning. 
Sterile 1.8 ml cryogenic vials and Mr. Frosty cell freezing contain-
ers were from Thermo Fisher Scientific (Pittsburgh, PA, USA).
Tissue culture-treated opaque white 384-well plates, 
catalog #353988, were from BD Falcon (Bedford, MA, USA), 
and MicroClime® environmental lids used with these plates were 
from Labcyte (Sunnyvale, CA, USA). Polypropylene (PP) plates 
were from Thermo Fisher Scientific Nunc (catalog #264573, 
non-sterile; and catalog #264574, sterile) and Axygen Scientific 
(Corning, NY, USA, catalog #P384-240SQ-C). CellTiter-Glo® 
and Nano-Glo® Dual-Luciferase® Reporter reagent kits were 
purchased from Promega (Madison, WI, USA). Antineoplastic 
antibiotic dactinomycin was purchased from AG Scientific (San 
Diego, CA, USA) for use as a cytotoxic control in cell viability 
assays. The glucocorticoid dexamethasone was purchased from 
R&D Systems (Minneapolis, MN, USA). Isopropanol used for 
pintool and tip washing was certified ACS Plus; ≥99.5% pure 
grade from Thermo Fisher Scientific.
Test Compounds
Screening Library
The Spectrum collection of 2,000 biologically active drugs and 
natural products was purchased from MicroSource Discovery 
Systems (Gaylordsville, CT, USA) as 10  mM stocks in DMSO 
in 96-well PP plates. A set of compound plates at 4  mM was 
generated by plate-to-plate transfer of 10 mM compound stocks 
into 96-well PP plates and dilution with DMSO. Using a Janus 
MDT (PerkinElmer, Waltham, MA, USA), the 96-well 4  mM 
plates were compressed into 384-well format by transfer of sets 
of four 96-well plates into a single 384-well plate. Each 384-well 
plate was filled quadrant by quadrant; for example, well A2 of 
each of four 96-well plates was transferred into wells A3, A4, B3, 
and B4, respectively, in one 384-well plate. The resulting 384-well 
compound plates each contained 20 μl of 4 mM compound in 
DMSO in columns 3–22 (320 compounds/plate), and 20 μl of 
DMSO in columns 1, 2, 23, and 24 reserved for controls.
All compound plates (and compound powders and solutions 
in vials) were stored at −30°C in desiccators containing Drierite 
(W. A. Hammond Drierite Co., Xenia, OH, USA). Prior to stor-
age, plates were sealed with Easy-Peel Heat Sealing Foil covers 
using an ALPS 50 V Microplate Heat Sealer (Thermo Scientific, 
Pittsburgh, PA, USA). For compound testing, plates were thawed 
in desiccators at room temperature (≤12 h) and centrifuged at 
250 × g for 5 min before removal of the foil cover. Immediately 
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after use, plates were re-sealed, returned to desiccators, and stored 
at −30°C.
PDE Inhibitors
PDE3 and PDE4 inhibitors were purchased from R&D Systems 
(Minneapolis, MN, USA). Cilostamide, milrinone, (R)-(−)-
rolipram, and Ro 20-1724 were part of the Tocris PDE inhibitor 
set and were obtained as 10 mM stocks in DMSO. Zardaverine, 
anagrelide (NSC number 724577), CDP 840, trequinsin, piclami-
last, YM 976, cilostazol, siguazodan, RS 25344, and ICI 63197 
were purchased as powders, from which 50 mM stocks in DMSO 
were prepared. (Due to limited solubility, cilostazol was dissolved 
at 40 mM in DMSO.)
Zardaverine and Anagrelide Analogs
The following zardaverine analogs were supplied through Ryan 
Scientific (Mount Pleasant, SC, USA): ChemDiv D216-0257, D216-
0505, and D216-0543; Life Chemicals F1967-0306 and F1967-
0458; Specs AA-504/34797002 and AG-219/36433016; Vitas-M 
Laboratory STK359621, STK902092, STK902095, STK931158, 
STK931862, STK932677, STK943767, STL102657, STL102658, 
STL141098, STL146832, STL160606, and STL214769. Zardaverine 
analog imazodan and anagrelide analog quazinone were from 
Sigma-Aldrich (St. Louis, MO, USA). Compounds were dissolved 
in DMSO to generate 50 mM stocks except for AA-504/34797002 
(16.7 mM), imazodan (12.5 mM), and quazinone (10 mM) due to 
lack of solubility at higher concentrations.
Cell Lines
Except as specified below, all cell lines were grown in DMEM 
supplemented with 4 mM l-glutamine, 10% FBS, 100 U/ml peni-
cillin, and 100 μg/ml streptomycin at 37°C in an atmosphere of 
5% CO2. Approval from the Nemours Biosafety Committee and 
Institutional Review Board was obtained before commencing the 
cell culture protocols described below (see also Human Subjects 
Protection).
CS242 ERMS (Initial)
Initially, patient-derived CS242 ERMS cells were established in 
culture in DMEM supplemented with 20% FBS, as described in 
Robbins et al. (8). Mutation analysis, short tandem repeat (STR) 
profiling, and fluorescence in situ hybridization verified that the 
established cells had the same genomic characteristics as the 
original tumor sample, notably homozygous p.G12A mutant 
HRAS and complete loss of maternal chromosome 11 (8). After 
five passages, cells at 30% confluence were grown for a further 
3  days in a T25 flask, followed by expansion into two 10 cm2 
dishes and continued growth and a media change every 3 days for 
a total of 9 days, after which time >70% confluence was reached. 
After removal of media by aspiration, cells were washed with 
PBS and detached by treatment with 0.25% trypsin. Detached 
cells were washed in media, pelleted at 200 × g for 5 min, and 
resuspended in freezing medium comprising 90% FBS and 10% 
DMSO. The resulting master cell bank (at passage 6 following 
expansion from T25, growth and detachment) was dispensed into 
1-ml cryogenic vials at 1–5 million cells/vial, frozen at −80°C for 
72 h, and transferred to vapor phase liquid nitrogen storage.
CS242 ERMS (Screening)
To generate cells optimized for high-throughput screening 
(HTS), one vial of frozen cells from the CS242 ERMS (initial) 
master cell bank was thawed in a 37°C water bath for 2  min, 
diluted by dropwise addition of 10 volumes of PBS, pelleted at 
200 × g for 5 min, resuspended in PBS, pelleted, resuspended in 
medium, and transferred to a T75 flask. Cells were grown to 70% 
confluence over 27 days, with media changes every 3 days. Cells 
were then detached by trypsin treatment as described above [see 
CS242 ERMS (Initial)] and split at 1:20 into T150 flasks, giving 20 
individual cultures at passage 7. After growth for a further 27 days 
with media changes every 3 days, cells reached 70% confluence 
and were detached and frozen as described above [see CS242 
ERMS (Initial)] to give a working cell bank at passage 8.
CS242 ERMS (Zardaverine Resistant)
To derive zardaverine-resistant cells, one vial of frozen cells 
from the CS242 ERMS (screening) cell bank was thawed as 
described above [see CS242 ERMS (Screening)] and grown to 
70% confluence over 3 days in a T75 flask. Cells were detached 
by trypsin treatment, counted with a hemocytometer using 
trypan blue exclusion (11), and seeded at 212,000/well in 2 ml 
of growth media in a 6-well plate. This seeding density was 
chosen to match 1,250 cells/well in 384-well format, which was 
found to be optimal for progressive growth during development 
of the cell viability assay used for screening (Cell Viability 
Assay Development). After overnight attachment to the plate, 
the resulting cells at passage 9 were treated with zardaverine at 
0.94 μM (~3 × IC50 obtained in 384-well plates) and incubated 
for 3  days, with media (containing zardaverine) changed after 
3 days. Cells were detached, split at 1:6 into a new 6-well plate, 
and the resulting cells at passage 10 were allowed to recover 
in the absence of zardaverine for 6  days, with a media change 
after 3  days. Cells were then treated with 15  μM zardaverine 
for 3 days, detached, split, and expanded into a T75 flask, and 
allowed to recover for 2  days in the absence of zardaverine. 
The resulting cells at passage 11 were treated with fresh media 
containing 15 μM zardaverine and incubated for 4 days at which 
time cells reached 70% confluence. Cells were detached and 
frozen as described above [see CS242 ERMS (Initial)] to give a 
master cell bank at passage 12. One vial of cells from the master 
cell bank was then used to generate a working cell bank. Cells 
were thawed into a T75 flask, and immediately maintained in 
the presence of 15 μM zardaverine in media. Cells were grown 
for 9  days, with media changes every 3  days, detached, and 
split at 1:10 into T150 flasks, giving 10 individual cultures at 
passage 13. After growth for 8  days in the presence of 15 μM 
zardaverine, with a media (and zardaverine) change after 4 days, 
cells reached 70% confluence and were detached and frozen to 
give a working bank of passage 14 zardaverine-resistant CS242 
ERMS at 5–10 million cells/ml per vial.
Other Cell Lines
Fibroblast cell lines (patient-matched CS242 and normal 
female) were established as described for CS242 ERMS (initial) 
culture [see CS242 ERMS (Initial)]. Mutation analysis and STR 
profiling validated HRAS as heterozygous at p.G12A or wild 
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type, respectively (data not shown). Other cancer cell lines not 
associated with CS were obtained for comparative studies: Rh18 
and Rh36 ERMS were a generous gift from Dr. Peter Houghton 
(Nationwide Children’s Hospital, Columbus, OH, USA); RD 
ERMS, T24 (bladder carcinoma) and HeLa (cervical carcinoma) 
were purchased from ATCC (Manassas, VA, USA). Rh36 ERMS 
and T24 were cultured in RPMI and McCoy’s 5A, respectively, 
supplemented with 4  mM l-glutamine, 10% FBS, 100  U/ml 
penicillin, and 100 μg/ml streptomycin.
Methods
Cell Viability Assay Development
CS242 ERMS Cell Growth Optimization
Cell growth in 384-well plates was assessed daily for 5  days to 
determine the optimal starting cell number giving progressive 
growth suitable for a 72-h cell viability assay. One vial of CS242 
ERMS cells was thawed from the screening bank and grown in 
a T75 flask until confluence was >70%, after which cells were 
detached using trypsin and counted as described above [see 
CS242 ERMS (Zardaverine Resistant)].
Cells were twofold serially diluted in media by gentle pipet-
ting in 15-ml conical tubes to give eight concentrations ranging 
from 250,000 to 1,950 cells/ml. Using an electronic 16-channel 
pipettor (Finnpipette Novus MCP16), 40 μl of each cell dilution 
was dispensed into two columns of a TC-treated opaque white 
384-well plate, giving a range of 10,000 to 78 cells/well. Columns 
1, 2, 23, and 24 were filled with media alone (40 μl/well). Five 
replicate plates were covered with MicroClime environmental 
lids (Labcyte) to minimize evaporation and incubated at 37°C, 
5% CO2 for 24, 48, 72, 96, and 120 h, respectively. A sixth plate 
was prepared for determination of cell viability at the time of cell 
seeding. To determine cell viability, plates were allowed to cool 
to room temperature for 1 h after removal from 37°C incubation, 
20 μl/well of CellTiter-Glo was added using a MicroFlo Select 
microplate reagent dispenser (BioTek, Winooski, VT, USA), and 
luminescence was measured after an additional 30 min at room 
temperature using an EnVision microplate reader (PerkinElmer, 
Waltham, MA, USA). Signal stability was confirmed by re-reading 
luminescence every 10 min for 2 h.
Optimization of Growth of Other Cell Lines
Growth of CS242 fibroblasts, normal female fibroblasts, RD 
ERMS, Rh18 ERMS, Rh36 ERMS, T24, and HeLa cells was 
evaluated similarly to that of CS242 ERMS. For each cell line, an 
optimal starting cell number was selected that gave progressive 
growth over at least 72 h, and a doubling time comparable to that 
of CS242 ERMS over this time.
Data Analysis
Luminescence values at each time point were converted to cell 
numbers using a standard curve. A linear standard curve was 
derived by serial dilution of cells in a 384-well plate (16 twofold 
dilutions from a top number of 20,000/well) and immediate 
addition of CellTiter-Glo and measurement of luminescence. 
Cell numbers were plotted and fit to a non-linear regression 
exponential growth equation using GraphPad Prism (GraphPad 
Software, San Diego, CA, USA). This fit enabled assessment of 
progressive growth and derivation of cellular doubling times. 
To validate that 72 h of cell growth would be suitable for a cell 
viability assay, Z′-factor analysis (12) was used to evaluate the 
signal window (defined as the difference between luminescence 
values corresponding to cell growth and no cells). The Z′-factor 
was calculated according to Eq. 1:
 
′ = −
+
−
+ −
+ −
Z 1 3 3( )
| |
,δ δ
µ µ
c c
c c  
where symbols represent the following: δc+: SD of high controls 
(with cells); δc−: SD of low controls (without cells); μc+: mean of 
high controls; μc−: mean of low controls.
Compound Screening
Assay Quality Control (QC)
Final validation of the CS242 ERMS cell viability assay for HTS was 
performed by testing QC plates containing the known cytotoxic 
agent dactinomycin at approximately its IC50. The IC50 of dactino-
mycin was determined using cells passaged once from the CS242 
ERMS (screening) cell bank [see CS242 ERMS (Screening)]. Cells 
were thawed, grown to 70% confluence over 3 days in a T75 flask, 
detached by trypsin treatment, seeded at 1,250 cells in 30 μl of 
media/well in 384-well opaque white TC plates, and allowed 
to attach overnight. Dactinomycin was twofold serially diluted 
from a 160 μM stock to give 16 dilutions in DMSO, which were 
added to pre-plated cells in two steps: intermediate dilution of 
50 nl added by pintool into 20 μl of media, followed by transfer 
of 10 μl of dactinomycin in media into assay plates to give final 
concentrations ranging from 100  nM to 3.1  pM. After 72  h of 
cell growth in the presence of dactinomycin, 20 μl of CellTiter-
Glo was added, and cell viability was determined as described 
above (see Cell Viability Assay Development). Percent viability 
was determined from luminescence values using high controls 
(no dactinomycin) and low controls (media alone; no cells), and 
IC50 values were calculated using four-parameter dose–response 
curve fitting analysis in GraphPad Prism.
Based on a calculated IC50 of 0.1  nM, dactinomycin was 
dispensed into QC plates containing attached cells to give a final 
concentration of 0.1  nM in all 320 test wells (columns 3–22). 
DMSO was added to the high control wells (columns 1 and 23) 
and low control wells (columns 2 and 24; media alone, no cells) 
by the same two-step addition via intermediate dilution as used 
for dactinomycin. Percent viability was determined as above after 
72 h of cell growth.
Compound Screening in Cell Viability Assay
The 2,000-compound Microsource Spectrum library was 
screened using a fresh batch of CS242 ERMS (screening) cells 
for each HTS run, prepared as described above (see Cell Viability 
Assay Development). Cells (1,250 in 30  μl media/well) were 
dispensed into columns 1 and 3–23 of 384-well opaque white TC 
plates using a MicroFlo Select reagent dispenser equipped with a 
5–2,500 μl cassette (BioTek, Winooski, VT, USA). Media alone 
was added to low control (background) wells in columns 2 and 
24. Plates were covered using MicroClime environmental lids 
(Labcyte), and cells were allowed to attach overnight (≤12 h) at 
37°C in an atmosphere of 5% CO2.
TaBle 1 | cell line panel.
cell line Description source ras 
mutation
CS242 embryonal 
rhabdomyosarcoma 
(ERMS) (initial)
ERMS; abdominal origin; 
pediatric
Nemours Homozygous 
HRAS p.G12A
CS242 ERMS 
(screening)
ERMS derived from CS242 
ERMS primary culture
Nemours Homozygous 
HRAS p.G12A
CS242 ERMS 
(zardaverine 
resistant)
Zardaverine-resistant ERMS 
derived from CS242 ERMS 
screening culture
Nemours Homozygous 
HRAS p.G12A
CS242 fibroblast Patient-matched skin 
fibroblast to CS242 ERMS; 
pediatric
Nemours Heterozygous 
HRAS p.G12A
RD ERMS ERMS of muscle origin; 
pediatric
American 
Type 
Culture 
Collection 
(ATCC)
Homozygous 
NRAS 
p.Q61H
Normal female 
fibroblast
Skin fibroblast; pediatric Nemours Wild type 
HRAS
Rh18 ERMS Non-syndromic ERMS; 
solid tumor from mouse 
xenograft; pediatric
Dr. Peter 
Houghton 
(Nationwide 
Children’s 
Hospital)
Wild type 
HRAS
Rh36 ERMS ERMS derived from 
paratesticular relapse; 
pediatric
Dr. Peter 
Houghton 
(Nationwide 
Children’s 
Hospital)
Heterozygous 
HRAS p.Q61K
T24 Transitional cell carcinoma 
of urinary bladder; geriatric
ATCC Homozygous 
HRAS p.G12V
HeLa Adenocarcinoma of cervical 
origin; adult
ATCC Wild type 
HRAS
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Compounds were delivered to columns 3–22 of assay plates 
containing attached cells via an intermediate dilution. Using 
a Janus MDT equipped with a 384-pin slotted pintool (V&P 
Scientific, San Diego, CA, USA), 50  nl was transferred from 
storage plates containing 4  mM compound in DMSO (see 
Screening Library) into 20  μl of media in sterile 384-well PP 
plates. Ten microliters of media plus compound were added to 
assay plates by tip transfer using a Janus MDT, giving a final test 
compound concentration of 2.5 μM. Likewise, DMSO was added 
to columns 1, 2, 23, and 24 for high and low controls, matching 
the 0.06% DMSO in the test wells. QC plates containing 0.1 nM 
dactinomycin (see Assay Quality Control (QC)) were added at 
the beginning and end of each screening run to monitor plate-
to-plate consistency. After 72 h of cell growth in the presence of 
test compounds, cell viability was determined following addition 
of 20 μl of CellTiter-Glo (see Cell Viability Assay Development).
Following two replicate screens of the Microsource Spectrum 
library, percent inhibition of each test compound was averaged, 
and hits were selected as possessing likely statistically significant 
activity based on a percent inhibition threshold of >30%. This 
threshold exceeded 3× the highest percent coefficient of variation 
of the plate controls observed in the assay plates. Due to the high 
5.6% hit rate based on the 30% threshold, selection of compounds 
for dose–response confirmation was based on a more stringent 
threshold of >85% inhibition, which reduced the hit rate to 3.1%.
Dose–Response Confirmation and Determination of 
Selectivity
Hits from the Microsource Spectrum library screen in CS242 
ERMS were tested in dose–response in CS242 ERMS and CS242 
fibroblasts. Using CS242 ERMS and CS242 fibroblast starting cell 
numbers of 1,250 and 313/well, respectively, cell viability was 
assayed using the compound screening protocol (see Methods), 
except that the 320 test wells in each plate comprised serial dilu-
tions of 20 test compounds, one per column. Compounds were 
cherry picked from 4 mM stocks (see Screening Library) using a 
Janus Varispan, and twofold serially diluted in DMSO to give 16 
dilutions ranging from 4,000 to 0.122 μM, which were added to 
pre-plated cells in two steps: intermediate dilution of 1.2 μl added 
by tip into 160 μl of media in PP plates, followed by tip transfer of 
10 μl of compound in media into assay plates to give final concen-
trations ranging from 7.5 μM to 0.23 nM. Dose–response curves 
and IC50 values were determined from percent viability data using 
four-parameter dose–response curve fitting analysis in GraphPad 
Prism. Fold selectivity of compound cytotoxicity in CS242 ERMS 
compared with CS242 fibroblasts was determined by dividing 
IC50 values in CS242 fibroblasts by IC50 values in CS242 ERMS.
PDE Inhibitor Panel
Phosphodiesterase inhibitors were twofold serially diluted in 
DMSO from 10, 40, or 50 mM stock solutions (see PDE Inhibitors). 
Compounds were added to pre-plated CS242 ERMS as described 
above (see Dose–Response Confirmation and Determination of 
Selectivity) to give 16 dilutions ranging from a top concentra-
tion of 18.8, 75, or 93.8 μM. Cell viability and IC50 values were 
determined according to Section “Dose–Response Confirmation 
and Determination of Selectivity.”
Cell Line Panel
Zardaverine and anagrelide were tested in 16-point dose–
response, comprising twofold dilutions from a top concentration 
of 7.5 μM, in a panel of malignant and non-malignant cell lines 
(Table 1). Compounds were tested in CS242 ERMS and RD ERMS 
seeded at 1,250 cells/well, and in CS242 fibroblast, normal female 
fibroblast, Rh18 ERMS, Rh36 ERMS, T24, and HeLa seeded at 
313 cells/well. Cells were exposed to compound for 72 h, and cell 
viability and IC50 values were determined as described above (see 
Dose–Response Confirmation and Determination of Selectivity). 
Viability of a separate plate of cells in the absence of test compound 
was measured at the time of compound addition to determine a 
luminescence value corresponding to the starting cell number. 
This allowed for identification of cytostatic effects after 72 h, in 
which high concentrations of a compound reduce luminescence 
only as far as a level corresponding to the starting cell number. In 
contrast, cytotoxic compounds reduce luminescence well below 
starting values, and ultimately to 0.
Mouse Mammary Tumor Virus Promoter (MMTV) 
Reporter Gene Assay
HeLa cells were seeded in 10 cm2 dishes at 2 million cells/dish, 
in phenol red-free DMEM containing 4 mM l-glutamine and 5% 
CS-FBS, and allowed to attach overnight. Using Lipofectamine 
FigUre 1 | growth curve of cs242 embryonal rhabdomyosarcoma 
cell line optimized for screening. Cells plated at 1,250/well in 384-well 
format were assessed for viability using CellTiter-Glo at the times shown. 
Raw luminescence data were converted to cell number using a standard 
curve, and data up to 96 h were fit to an exponential growth curve using the 
exponential growth equation in GraphPad Prism. Data points represent 
mean ± SD of 48 (0 h) or 32 replicates (remaining time points).
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3000, cells were transfected with one of three combinations of 
vectors: GL4.36[luc2P/MMTV/Hygro] and pNL1.1.TK[Nluc/
TK], pGL4.54[luc2/TK] and pNL1.1.TK[Nluc/TK], or 
pNL1.1.TK[Nluc/TK] alone. Transfection proceeded for 24  h, 
after which the cells were harvested and seeded into 384-well 
opaque white plates by adding 2,500  cells/well in 20  μl fresh 
media to 5 μl media containing serially diluted zardaverine (15 
point, twofold serial dilution, 0.12 nM to 2.0 μM final concen-
tration) and dexamethasone (0 or 100 nM final concentration). 
After 12 and 24  h, plates were assayed for expression of firefly 
and NanoLuc luciferases using Nano-Glo® Dual-Luciferase® 
Reporter, or cell viability using CellTiter-Glo.
human subjects Protection
Ethical approval through the Nemours Institutional Review 
Board was obtained under protocol Nemours IRB1, IRB #: 2005-
051. All patients were enrolled into this approved protocol. Tissue 
samples were obtained under this protocol as approved. After 
informed signed consent is obtained from the parent or legal 
guardian, the individual is assigned an identification number. 
The patient specific information and the code to the anonymous 
numerical identifier are kept by the principal investigator and 
research coordinator in a secure database. All tissue or DNA 
samples are labeled only with this anonymous identifier. The 
laboratory identifies samples using this anonymous identifier. 
Cell lines derived from de-identified samples were subsequently 
used in the research reported in this manuscript.
resUlTs
cell Viability assay Development
A cell viability assay for CS242 ERMS was developed in which the 
initial patient-derived CS242 culture was conditioned for HTS. 
Cell viability was measured using CellTiter-Glo, which gives a 
luminescent measure of intracellular ATP levels. CS242 ERMS 
(screening) cells in 384-well microplates gave robust growth over 
5 days. The data up to 96 h were fit by non-linear regression to 
an exponential growth equation in GraphPad Prism and showed 
an excellent fit to a curve representing exponential growth 
with a constant doubling time of 32.5 h. The data at 120 h were 
excluded from the fit because it appeared that cell growth began 
to slow after 96 h (Figure 1). Similarly, cell viability assays were 
optimized for CS242 fibroblasts, normal female fibroblasts, RD 
ERMS, Rh18 ERMS, Rh36 ERMS, T24, and HeLa cells (data not 
shown). Moreover, Z′-factors in excess of 0.75 throughout 5 days 
of CS242 ERMS growth (Figure S1A in Supplementary Material) 
were indicative of a consistent and robust assay (12). Cell growth 
over 4 days in the presence of a range of concentrations of DMSO 
showed that up to 0.5% DMSO had no effect on cell viability 
(Figure S1B in Supplementary Material), allowing for a screening 
protocol to be designed in which test compounds in 100% DMSO 
may be added to cells via a single intermediate dilution in media. 
Adding CellTiter-Glo to a range of cell dilutions, and reading 
the resulting luminescence signal at intervals for 2 h thereafter 
provided a linear cell standard curve, and confirmed signal sta-
bility (Figure S1C in Supplementary Material). The cell viability 
assay was validated for HTS by testing of QC plates containing 
the cytotoxic agent dactinomycin. Following determination of 
an IC50 of 0.1 nM by dose–response testing of dactinomycin in 
CS242 ERMS (Figure S2A in Supplementary Material), QC plates 
were set up by dispensing this concentration of dactinomycin into 
all 320 test wells of assay plates. Figures S2B,C in Supplementary 
Material show that percent viability was consistent at approxi-
mately 65% within each QC plate and between 12 QC plates 
tested in separate experiments.
compound screening
CS242 ERMS (screening) cells were treated with the Spectrum 
library of 2,000 FDA-approved drugs, clinical candidates, 
and pharmacologically active natural products (Microsource 
Discovery, Gaylordsville, CT, USA). Screening at 2.5 μM of test 
compound gave an excellent correlation between replicate plates 
(Figure 2A). A threshold of >85% inhibition of viability (orange 
symbols) gave 58 hits to retest in dose–response and profile for 
selectivity in a panel of cell lines. Figure 2B shows that every plate 
gave highly consistent data statistics. Coefficients of variation 
(%CV) were all below 10%, well within acceptable limits, and 
Z′-factors in excess of 0.7 confirmed assay robustness (12). Also, 
not shown in the figure, the control signal was >50-fold above 
background, and cell number doubling times were consistent at 
approximately 32 h in all plates.
selectivity Profiling of hits from cs242 
erMs Viability screen
All 58 hits giving >85% inhibition of CS242 ERMS (HTS) cell 
viability at 2.5 μM were tested in dose response in CS242 ERMS 
and patient matched CS242 fibroblasts. Ten compounds showed 
≥twofold lower IC50 in CS242 ERMS (homozygous p.G12A 
mutant HRAS) than in patient-matched CS242 fibroblasts 
(heterozygous p.G12A mutant HRAS) (Table  2; Figure S3 in 
FigUre 2 | screening of Microsource spectrum library in cs242 embryonal rhabdomyosarcoma. Compounds were screened at 2,500 nM in duplicate 
plates. (a) Correlation plot on which active compounds are shown based on two inhibition thresholds: >85 and >30% on each plate. Compounds giving <30% 
inhibition in one or both test wells were considered inactive. Linear regression showed a highly significant correlation between duplicate sets of screening data 
(R2 = 0.85). (B) Statistical analyses of test plates (numbered 1–7) and quality control (QC) plates (numbered QC1 and QC2) in replicate sets 1 and 2 (black and red, 
respectively). (Top) %CV, defined as SD ÷ mean expressed as a percentage (calculated from 32 replicate control wells containing cells but no test compound in each 
plate). (Bottom) Z′-factor, calculated as described in Section “Data Analysis.” A threshold Z′-factor value of 0.5 is shown by a dotted line on the graph; values >0.5 
indicate a robust and reproducible assay.
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Supplementary Material). The PDE inhibitor zardaverine showed 
remarkable selectivity for CS242 ERMS, inhibiting cell viability 
with an IC50 of 206 nM while displaying no measurable activity in 
patient-matched non-malignant CS242 fibroblasts. Several topoi-
somerase inhibitors and cardiotonic agents also showed some 
selectivity, but follow-up studies were focused on zardaverine by 
virtue of its striking activity profile.
Testing of other PDe inhibitors in cs242 
erMs
Zardaverine inhibits PDE3 and 4 (9, 10), so a selection of other 
PDE3 and PDE4 inhibitors was tested to determine whether 
they were cytotoxic to CS242 ERMS. Table  3 shows that only 
zardaverine and anagrelide were potent in CS242 ERMS; a few 
others had marginal activity, but most showed no measurable 
inhibition. Taken together, these data suggested that inhibition of 
the enzymatic activity of PDE3 or 4 may not be sufficient for cell 
killing in CS242 ERMS and that zardaverine and anagrelide may 
be also modulating other target(s). The structures of zardaverine 
and anagrelide shown in Figure 3 share some similar features, 
suggesting these compounds may interact with a target in CS242 
ERMS that is not accessible to the inactive PDE inhibitors.
cellular selectivity Profiling of Zardaverine 
and anagrelide
To further define selectivity for CS242 ERMS, zardaverine and 
anagrelide were tested in the panel of cell lines listed in Table 1. 
This panel comprised ERMS harboring various RAS mutations 
or wild type RAS; non-malignant fibroblasts harboring het-
erozygous mutant HRAS or wild type HRAS; and T24, a bladder 
carcinoma cell line harboring homozygous mutant HRAS. In 
addition, we included cervical carcinoma-derived HeLa cells, 
because zardaverine had been reported as cytotoxic in this cell 
line (27) (Figure 4). The remarkable selectivity of zardaverine for 
CS242 ERMS over the patient-matched CS fibroblast cell line is 
shared by anagrelide. Moreover, both compounds showed potent 
cytotoxicity in HeLa cells, but no discernible effect on any of the 
other cell lines tested. An interesting difference between the two 
compounds is that zardaverine showed complete killing of CS242 
ERMS at high concentrations, whereas cell viability remained at 
25% even at the highest concentrations of anagrelide. The lumi-
nescence values determined after 72 h at the highest anagrelide 
concentrations equal the luminescence measured at the starting 
cell number on day 0 of the assay. Therefore, the data are consist-
ent with anagrelide exerting a cytostatic rather than a cytotoxic 
effect in CS242 ERMS, although we have not verified this pos-
sibility. The dose–response profile of anagrelide is consistent with 
the Microsource Spectrum library screening data. Anagrelide was 
present in the library, but it was not found in the top tier of hits 
(>85% inhibition, shown in orange in Figure 2A); instead it gave 
81% inhibition.
The cytotoxicity profiles of zardaverine and anagrelide 
among the cell lines tested suggest that RAS mutation status 
is not the primary determinant of compound activity. Activity 
was observed in both CS242 ERMS and HeLa, yet CS242 ERMS 
harbors homozygous mutant HRAS, whereas HeLa contains wild 
type HRAS. Moreover, neither compound had any effect on the 
T24 cell line, which harbors homozygous mutant HRAS.
cs242 erMs comprises Zardaverine 
resistant and sensitive subpopulations of 
cells
Passaging CS242 ERMS in the presence and absence of zardav-
erine revealed the presence of subpopulations of cells differing 
in their sensitivity to compound treatment. The CS242 ERMS 
(screening) population generated by passaging the initial 
TaBle 3 | cytotoxicity of phosphodiesterase (PDe) inhibitors in cs242 
embryonal rhabdomyosarcoma (erMs) compared with reported PDe 
ic50.
compound cs242 erMs viability reported PDe inhibition
ic50 (nM)a PDe ic50 (nM) reference
Anagrelide 68.1 ± 1.6 3 36 (13)
Zardaverine 409 ± 24.3 3/4 1,500/930b (14)
CDP 840 27,800 ± 207 4 12 (15)
Trequinsin 36,500 ± 2,110 3 0.25 (16)
Piclamilast 55,800 ± 1,480 4 1 (17)
YM 976 60,700 ± 3,950 4 2.2 (18)
Cilostamide >18,800 3 27 (19, 20)
Milrinone >18,800 3 56 (21)
(R)-(−)-rolipram >18,800 4 220 (22)
Ro 20-1724 >18,800 4 2,000 (23)
Cilostazol >93,800 3 200 (24)
Siguazodan >93,800 3 117 (21)
RS 25344 >93,800 4 0.28 (25)
ICI 63197 >93,800 4 35 (26)
aData represent mean ± SD (n = 3).
bValues for PDE3B and PDE4B. Also tested in PDE4D (390 nM).
Anagrelide (13); zardaverine (14); CDP 840 (15); trequinsin (16); piclamilast (17); YM 
976 (18); cilostamide (19, 20); milrinone (21); (R)-(−)-rolipram (22); Ro 20-1724 (23); 
cilostazol (24); siguazodan (21); RS 25344 (25); ICI 63197 (26).
TaBle 2 | selective hits from cs242 erMs screening.
Microsource iD ic50 (nM)a Fold selectivityb compound name Pharmacological activity
cs242 erMs cs242 fibroblast
1506056 206 ± 4.9 >7,500 >36.4 Zardaverine PDE3 and 4 inhibitor
1505820 1.8 ± 0.1 51.2 ± 13.2 28.4 Topotecan hydrochloride Antineoplastic; topoisomerase 1
1505708 7.0 ± 1.5 128 ± 17.6 18.3 Epirubicin hydrochloride Antineoplastic; topoisomerase 2
1504123 12.7 ± 1.5 113 ± 22 8.9 10-Hydroxy-camptothecin Antineoplastic; topoisomerase 1
1501205 47.7 ± 4.9 196 ± 16.5 4.1 Lanatoside c Cardiotonic
100749 15.3 ± 1.5 41.5 ± 4.9 2.8 Strophanthidinic acid lactone acetate Cardiotonic
1500986 111 ± 12.5 280 ± 41.5 2.5 Gitoxin Cardiotonic
100688 407 ± 5 903 ± 27.7 2.2 Digoxigenin Cardiotonic
100584 97.8 ± 7.2 196 ± 14.5 2.0 Gitoxigenin diacetate Cardiotonic
100291 120 ± 4.2 237 ± 18.6 2.0 Strophanthidin Cardiotonic
aData represent mean ± SD (n = 3).
bIC50 in CS242 fibroblasts/IC50 in CS242 ERMS.
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patient-derived culture was the most sensitive. Passaging CS242 
ERMS (screening) in the presence of zardaverine generated a 
CS242 ERMS (zardaverine resistant) population that survived 
doses of zardaverine lethal to CS242 ERMS (screening). The 
initial cell population showed intermediate zardaverine sensitiv-
ity (Figure  5). Interestingly, cell populations passaged in the 
presence of zardaverine also acquired resistance to anagrelide, 
further evidence that the two compounds share a common target. 
Nevertheless, there may be differences between the mechanism 
of action; anagrelide differs from zardaverine in that it appears 
cytostatic in CS242 ERMS (screening) and inactive in CS242 
ERMS (initial). Both the rate at which zardaverine resistance 
appeared during cell culture and the shapes of the dose–response 
curves in Figure 5 suggest that the CS242 ERMS (initial) cells 
comprise a mixture of zardaverine-sensitive and zardaverine-
resistant populations. The CS242 ERMS (initial) zardaverine 
dose–response (red curve) appears to level off at 40% cell viability 
at high concentrations of compound, consistent with killing of 
only 60% of the cells present after 72 h. Passaging CS242 ERMS 
(initial) cells to optimize cell growth conditions enriched the 
zardaverine-sensitive population from 60% of the total popula-
tion to almost 100% (black curve). Conversely, further passaging 
of the resultant CS242 ERMS (screening) cells in the presence of 
zardaverine killed the CS242 ERMS (screening) cells and favored 
the remaining zardaverine-resistant cell population (blue curve).
Cytogenetic analysis of the subpopulations of CS242 ERMS 
with varying sensitivity to zardaverine revealed that each 
population harbored homozygous mutant HRAS and showed 
the complete loss of maternal chromosome 11 typically found in 
this CS-derived ERMS, confirming that the sensitive and resistant 
cell populations originate from the same tumor (data not shown). 
Nevertheless, the precise nature of the cells within each popula-
tion and the determinants of zardaverine sensitivity remain to be 
elucidated.
correlation of activity of Zardaverine and 
analogs between cs242 erMs and hela 
cells
We tested zardaverine in cervical carcinoma-derived HeLa cells 
because it had been previously reported as cytotoxic in these 
cells (27). Strikingly, CS242 ERMS and HeLa were the only two 
cell lines tested in which zardaverine was cytotoxic (Figure 4). 
The cytotoxicity of zardaverine in HeLa is clearly not mediated 
through an effect on mutant HRAS, given that wild type HRAS 
is present in HeLa cells. This observation raised the possibility 
that zardaverine cytotoxicity in CS242 ERMS is also not mediated 
through mutant HRAS. Therefore, we decided to explore whether 
a similar mechanism might account for zardaverine’s cytotoxicity 
in both CS242 ERMS and HeLa cells. In the absence of specific 
target information or a measure of target engagement, correlation 
between structure–activity relationships upon compound testing 
in two different assays is a reliable indicator that the same target 
mediates compound activity in both. A substructure search in the 
PubChem database (28) identified a selection of commercially 
available zardaverine analogs (Figure 3). These were purchased 
FigUre 3 | structures of zardaverine, anagrelide, and analogs. Compound numbers correspond with those listed in Table 4.
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and tested in both CS242 ERMS and HeLa cells (Table 4). We 
observed an excellent correlation between IC50 values obtained 
in both (Figure 6), providing evidence that the compounds share 
a target common to both cell types.
evaluation of glucocorticoid receptor 
(gr) activation as a Possible Target of 
Zardaverine
A search of the PubChem database suggested that inhibition of GR 
activation might mediate cell killing by zardaverine in HeLa cells. 
Aside from PDE inhibition, the only sub-micromolar activity of 
zardaverine reported as confirmed in PubChem is decrease in 
HeLa cell number (29). Inhibition of GR activation in engineered 
HeLa cells was reported as inconclusive (30), but close inspection 
of the dose–response data suggested to us that zardaverine was 
active in this screen, with an IC50 of 0.3 μM closely matching our 
data. Interestingly, the PDE inhibitors anagrelide and cilostamide 
were also tested in the GR activation screen and were highly 
active and inactive, respectively, consistent with our CS242 ERMS 
results. We were encouraged that HeLa cells in the GR activation 
screen were treated with test compounds for only 18 h, because 
we had observed that the cytotoxic effects of zardaverine in HeLa 
cells were not apparent before 24 h. Therefore, we reasoned that 
zardaverine may inhibit GR activation as a precursor to induc-
tion of cell death, and it might be possible to observe an effect of 
zardaverine on GR activation prior to cell killing.
We selected the inducible GL4.36[luc2P/MMTV/Hygro] vec-
tor to determine whether zardaverine inhibited gene expression 
driven by GR activation. This vector expresses firefly luciferase 
under the control of the MMTV, which contains steroid response 
elements that activate gene expression in response to glucocor-
ticoids such as dexamethasone. A protein degradation sequence 
(PEST) (31) tagged onto the luciferase results in protein turnover 
with a half-life of approximately 1 h (32), thereby ensuring a rapid 
assay response. The pGL4.54[luc2/TK] vector served as a control 
for global effects on gene expression. This vector expresses firefly 
luciferase under the control of a herpes simplex virus thymidine 
kinase (HSV-tk) promoter, which does not require induction 
FigUre 5 | Zardaverine and anagrelide sensitivity in subpopulations of cs242 embryonal rhabdomyosarcoma (erMs). Graphs show effects of (a) 
zardaverine or (B) anagrelide on viability after 72 h exposure to compound of three populations of CS242 ERMS: initial cells from patient-derived tissue (red), cells 
optimized for screening (black), and screening cells subsequently passaged in the presence of zardaverine (blue). Compounds were screened in triplicate; three 
separate curves are shown, each fit to a single replicate data set. Mean IC50 values (±SD) shown on the graphs were obtained by averaging each set of three curve 
fits.
FigUre 4 | Profiling of (a) zardaverine and (B) anagrelide in a panel of malignant and non-malignant cell lines. Table 1 lists the RAS mutation status of 
each cell line: homozygous mutant, heterozygous mutant, or wild type. Cells were treated with compound for 72 h prior to viability assessment using CellTiter-Glo. 
Compounds were screened in triplicate; three separate curves are shown, each fit to a single replicate data set. Mean IC50 values (±SD) shown on the graphs were 
obtained by averaging each set of three curve fits.
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by dexamethasone. Luciferase expressed by pGL4.54[luc2/
TK] lacks a PEST sequence, resulting in a 4-h half-life (32). 
Both firefly luciferase expressing cell groups also contained the 
pNL1.1.TK[Nluc/TK] vector expressing NanoLuc luciferase 
from the HSV-tk promoter, and in addition we included a set of 
control cells expressing only NanoLuc and not firefly luciferase. 
We initially thought to utilize NanoLuc as an internal control to 
monitor consistency between cell preparations, but its extreme 
stability and long half-life of approximately 7 days make it unsuit-
able (33).
HeLa cells transfected with the GL4.36[luc2P/MMTV/
Hygro] vector gave minimal luciferase expression in the 
absence of dexamethasone. Titration of dexamethasone gave a 
concentration-dependent increase in luciferase expression up to a 
maximal level at 100 nM and above (Figure S4 in Supplementary 
Material). As expected, cells containing pGL4.54[luc2/TK] gave 
robust luciferase expression in the absence of dexamethasone. 
Therefore, the effect of zardaverine on luciferase expression in 
response to GR activation was determined in cells transfected 
with GL4.36[luc2P/MMTV/Hygro] and treated with 100  nM 
dexamethasone. Zardaverine showed a strong effect after only 
12 h, and after 24 h potently and completely reversed dexametha-
sone activation of luciferase expression with an IC50 of 7.7 nM 
(Figure  7A). However, substantial reduction of expression in 
cells under the control of pGL4.54[luc2/TK] was also observed 
after 12 h (Figure 7B, red), and by 24 h this constitutive luciferase 
expression was almost completely inhibited with an IC50 of 8.0 nM 
(Figure 7B, black). Zardaverine treatment of control HeLa cells 
containing only the NanoLuc vector showed the expected mini-
mal effect on cell viability after 12 h, and a partial effect after 24 h 
(Figure 7C). Levels of the stable NanoLuc luciferase were unaf-
fected by zardaverine in all three cell populations (representative 
data shown in Figure S5 in Supplementary Material). Based on 
the minimal difference between the effects of zardaverine on 
dexamethasone-dependent and dexamethasone-independent 
luciferase expression, we concluded that zardaverine does not 
specifically inhibit GR activation, but instead exerts a global effect 
on gene expression prior to cell killing. The longer time required 
to completely inhibit constitutive as compared with inducible 
luciferase expression [24-h curve in Figure 7B (black) resembles 
12-h curve in Figure 7A] is most likely related to the longer half-
life of the constitutively expressed luciferase.
FigUre 6 | correlation of rank-order compound potency between 
cs242 embryonal rhabdomyosarcoma (erMs) and hela cells. 
Anagrelide, zardaverine, and analogs (structures shown in Figure 3) were 
tested in dose–response for their effects on viability on CS242 ERMS and 
HeLa cells. Calculated IC50 values are listed in Table 4. Each point on the 
graph represents one compound, plotted according to IC50 in CS242 ERMS 
(x-axis) and IC50 in HeLa cells (y-axis). Data represent mean ± SD for three 
replicates. (No error bars are shown for the two compounds in the top 
right-hand corner of the graph because the IC50 values were outside the 
range of compound concentrations tested. In these cases, the x–y 
coordinates of the data points shown represent the top concentration tested 
in each cell line.) Linear regression revealed a highly significant correlation 
(R2 = 0.85).
TaBle 4 | cytotoxicity of zardaverine, anagrelide, and analogs in cs242 
embryonal rhabdomyosarcoma (erMs) and hela cells.
compound 
numbera
cs242 erMs hela
ic50 (nM)b % Viability  
(max conc)c
ic50 (nM)b
3 (anagrelide) 58 ± 4 34.7 ± 1.5 6 ± 1
1 (zardaverine) 262 ± 15 10.0 ± 0.7 25 ± 3
4 (quazinone) 535 ± 60 56.4 ± 0.8 62 ± 7
13 596 ± 209 12.5 ± 0.0 11 ± 12
21 911 ± 13 9.7 ± 0.8 56 ± 6
17 1,020 ± 54 11.2 ± 0.3 56 ± 11
16 1,020 ± 97 15.3 ± 1.2 43 ± 8
23 1,210 ± 62 22.7 ± 0.4 111 ± 6
12 1,250 ± 148 49.6 ± 1.8 106 ± 14
2 (imazodan) 1,370 ± 460 71.5 ± 1.2 124 ± 6
9 1,430 ± 99 15.6 ± 1.3 167 ± 9
20 2,100 ± 220 31.1 ± 0.8 183 ± 32
14 2,160 ± 646 58.6 ± 2.3 99 ± 22
19 2,570 ± 308 40.9 ± 1.4 150 ± 17
6 2,810 ± 224 53.0 ± 1.3 289 ± 11
11 3,420 ± 111 41.2 ± 1.0 289 ± 25
10 3,980 ± 515 30.2 ± 0.1 384 ± 52
18 5,180 ± 1,480 31.1 ± 19.1 323 ± 29
15 9,560 ± 467 53.3 ± 2.7 866 ± 96
8 17,200 ± 4,200 50.0 ± 0.0 1,260 ± 58
7 29,200 ± 5,040 50.0 ± 0.0 2,010 ± 449
5 40,000 ± 2,110 60.0 ± 0.0 756 ± 88
24 >31,300 96.8 ± 2.1 >31,300
22 >93,800 97.2 ± 1.8 >93,800
aNumbers correspond to structures shown in Figure 3.
bData represent mean ± SD (n = 3).
cData represent % viability at the maximum concentration of compound tested, 
which was 93,800 nM except in the case of compounds 1, 3, and 4 (18,800 nM), 2 
(23,400 nM), and 24 (31,300 nM).
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DiscUssiOn
The purpose of screening CS-derived ERMS cells harboring 
mutant HRAS using a simple phenotypic readout of cell viabil-
ity was to identify compounds adversely affecting cell viability 
by unanticipated mechanisms of action, and thereby uncover 
novel targets to advance understanding of ERMS biology and 
improve treatment options. Our discovery of potent cell killing 
by zardaverine and apparent cell growth arrest by anagrelide 
offers the possibility of repurposing these compounds for treat-
ment of ERMS in children with CS. Both compounds were also 
cytotoxic in HeLa cells but had no effect on any of the other 
cell lines tested. These compounds were originally developed 
as PDE inhibitors (9, 10): zardaverine underwent clinical test-
ing as an asthma therapeutic, while anagrelide was approved 
for treatment of essential thrombocytosis (34, 35). However, 
the cell growth arrest and killing we observed in CS-derived 
ERMS may be mediated through another mechanism in addi-
tion to inhibition of the enzymatic activity of PDEs. We found 
that many PDE inhibitors equally potent as enzyme inhibi-
tors compared to zardaverine had no effect on CS242 ERMS 
(Table  3). However, these results should be interpreted with 
caution. We have not confirmed that the PDE inhibitors we 
purchased are active in our hands against the isolated enzymes. 
Moreover, the PDEs are a large family of enzymes and subtypes, 
with wide-ranging biological functions that depend on cel-
lular localization as well as structural features. PDEs and their 
properties have been described extensively in several excellent 
reviews (36–38). A comprehensive study of zardaverine in 
a panel of PDEs found that zardaverine was reasonably but 
not absolutely selective for PDE3 and PDE4. The most potent 
inhibition was against PDE3B, PDE4B, and PDE4D, with IC50s 
of 1500, 930, and 390 nM, respectively, but modest inhibition 
(IC50s of 14–160 μM) was observed against PDEs 5A, 8A, 10A, 
and 11A (14). Therefore, based on the information in Table 3 
alone, we cannot rule out that the cytotoxicity of zardaverine in 
CS242 ERMS is mediated through inhibition of a PDE3 or PDE4 
subtype in a specific cellular location, or another PDE not inhib-
ited by the other compounds tested. Nevertheless, these results 
raised the intriguing possibility that zardaverine and anagrelide 
act on a hitherto unexpected molecular target, either through 
a mechanism in which PDE inhibition is not involved at all, or 
mediated by a cooperative effect between PDE inhibition and 
another target present in CS242 ERMS and HeLa but not the 
other cell lines tested.
A recent report published while this manuscript was in prepa-
ration provides compelling evidence for modulation of a second 
target mediated through PDE inhibition, at least in the squamous 
cell carcinoma-derived HeLa cell line (39). Zardaverine, anagre-
lide, and a zardaverine analog dubbed DNMDP were cytotoxic to 
HeLa and certain lung cancer and melanoma cell lines but had no 
effect on most of a panel of 766 cancer cell lines. Consistent with 
our results, other equally potent inhibitors of PDE enzymatic 
activity were not cytotoxic. Chemogenomic analysis revealed a 
strong correlation with expression of both PDE3A and SLFN12 
in the sensitive cell lines. The overall conclusion of the study was 
that DNMDP exerts two functional effects upon binding to the 
FigUre 7 | Zardaverine dose–response testing in hela reporter 
assays. (a) HeLa cells transfected with GL4.36[luc2P/MMTV/Hygro] and 
pNL1.1.TK[Nluc/TK] were assayed for firefly luciferase activity 12 h (red) and 
24 h (black) after treatment with zardaverine in the presence of 100 nM 
dexamethasone; (B) HeLa cells transfected with pGL4.54[luc2/TK] and 
pNL1.1.TK[Nluc/TK] were assayed for firefly luciferase activity with OneGlo 
12 h (red) and 24 h (black) after treatment with zardaverine; (c) HeLa cells 
transfected with pNL1.1.TK[Nluc/TK] were assayed for cell viability with 
CellTiter-Glo 12 h (red) and 24 h (black) after treatment with zardaverine. Data 
are represented as percent activity compared to controls without zardaverine 
(n = 3, average ± SEM; in some cases the error bars are obscured beneath 
the plot symbol).
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enzyme active site of PDE3A: in addition to the “expected” inhi-
bition of the enzymatic PDE activity, this compound enhances 
binding of SLFN12 to PDE3A through an allosteric effect. How 
PDE3A recruitment of SLFN12 results in tumor cell death is still 
to be determined.
Although we do not yet have direct evidence for a connection 
between PDE3A–SLFN12 binding and zardaverine cytotoxicity 
in CS242 ERMS, our findings are consistent with this interaction 
being important in CS242 ERMS as well as HeLa. Compound 
testing results suggest that zardaverine, anagrelide, and analogs 
cause cytotoxicity and cell growth arrest in CS242 ERMS and 
HeLa through the same mechanism. We determined potency of 
a series of analogs in both cell types; correlation of the rank-order 
potency of a series of compound analogs between two assays is 
generally a robust and reliable indicator of a common mechanism 
of action. We purchased a substantial number of analogs closely 
related structurally to zardaverine and one analog of anagrelide 
(Figure 3). The effects of zardaverine, anagrelide, and these ana-
logs on cell viability correlated strongly between CS242 ERMS 
and HeLa (Figure 6), suggesting that all compounds act on the 
same target(s) in both cell lines.
An earlier study also reported cytotoxicity of zardaverine in 
HeLa cells but did not suggest the involvement of a non-PDE 
target (27). The authors attributed cell killing to PDE inhibition 
alone. However, these conclusions were based on activity of six 
PDE inhibitors among hits from the LOPAC library (Sigma, St. 
Louis, MO, USA). The LOPAC library contains another 25 known 
PDE inhibitors, and there is no mention of cytotoxicity in HeLa 
cells associated with these compounds.
In a third study of zardaverine in cancer, treatment of hepato-
cellular carcinoma cell lines led to potent and selective cytotoxic-
ity (40). Consistent with our results, zardaverine killed certain 
cell lines but not others, whereas other PDE inhibitors had no 
cytotoxic effect. Selective killing by zardaverine in hepatocellular 
carcinoma cell lines was linked to cell cycle arrest and subsequent 
induction of apoptosis by a mechanism independent of inhibition 
of PDE enzymatic activity. It was postulated that cell cycle arrest 
at G0/G1 and subsequent apoptosis was due to low expression 
of retinoblastoma protein (Rb) and perturbation of Rb-regulated 
signaling. To determine whether Rb mediates zardaverine 
cytotoxicity in CS242 ERMS, we measured levels of total and 
phosphorylated Rb in zardaverine-sensitive CS242 ERMS as well 
as in zardaverine-resistant CS242 ERMS and patient-matched 
fibroblasts. However, using western blotting, we saw no signifi-
cant differences between compound treated and untreated cells 
(data not shown).
To reach beyond the peer-reviewed literature, we searched the 
PubChem database (http://pubchem.ncbi.nlm.nih.gov) for fur-
ther insights into the mechanism of cytotoxicity of zardaverine 
and anagrelide in CS242 ERMS and HeLa. Interestingly, zard-
averine showed inhibitory activity in a HeLa cell-based reporter 
gene screen for GR activation, suggesting that GR signaling 
might be involved in cell killing by zardaverine (30). To test this 
hypothesis, we set up a reporter gene assay in which luciferase 
expression in HeLa cells was dependent on GR activation, and a 
counterscreen comprising constitutive expression of luciferase. 
We found that zardaverine inhibited inducible and constitu-
tive luciferase expression with almost identical IC50 values and 
dose–response profiles (Figure 7), leading us to conclude that the 
effects on gene expression preceding cell killing by zardaverine 
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are non-specific and not mediated through a specific effect on 
GR activation.
Zardaverine is a potent cytotoxic agent in CS242 ERMS and 
appears to be quite selective in its action. No other sarcoma 
cell lines were affected by zardaverine, neither in our panel 
(Figure 4), nor in the panel of 766 cell lies tested by de Waal 
et al. (39). However, what is not clear is whether the susceptibil-
ity of CS242 ERMS is shared by ERMS arising from other 
CS patients. The Nemours CS registry and tissue repository 
contains ERMS from eight patients (41), but to date the only 
established culture is that from patient CS242. Moreover, we 
have shown that CS242 contains a subpopulation of cells that 
are not affected by zardaverine (Figure 5). Further study of the 
mechanism of action of zardaverine in CS242 ERMS should 
provide insights into the biology of CS-derived ERMS, but 
the cellular susceptibilities revealed will not be exploitable 
therapeutically until we establish the frequency with which 
they arise in other cases of CS-derived ERMS. If we are able 
to extend the study of zardaverine to additional patient samples, 
the selectivity of zardaverine in CS242 ERMS may offer the 
possibility of a therapeutic option tailored to children suffering 
from CS-derived high-risk ERMS.
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